Sign in
Not yet taking people in United StatesPhase 2

MitoQ Supplementation for Microvascular Health and Stroke Recovery

Key facts

Who runs it
Medical College of Wisconsin
Where
Milwaukee, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
50 people, planned
Starts
1 Jan 2027
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • MitoQ
  • Placebo
Record updated
16 November 2026

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age 18-85 years
  • Cortical or subcortical stroke ≥ 6 months ago
  • Follows 2-step command
  • English speaking

Who cannot take part

  • Heart attack <1 year ago
  • History of other neurological disease
  • Other significant medical condition likely to influence study or jeopardize safety as assessed by Primary Investigator
  • Unable to walk 10 meters without physical assistance (able to use assistive device)
  • Unable to perform HIIE
  • Head Trauma < 6 months ago
  • Resting BP ≥ 180/100 mmHg
  • Pregnant and/or breastfeeding
  • Unable to obtain MCAv signal

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in United States

  • Medical College of WisconsinMilwaukee, United StatesContact: Matthew Durand, PhDNot yet recruiting

About the trial

What the trial wants to find out

Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows an antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.

The 2 groups in the trial

  • Antioxidant Supplement - MitoQTreatment being tested

    The investigators will be measuring how an over-the-counter antioxidant supplement, called MitoQ, affects how blood flow responds to movement and exercise. Participants will orally ingest MitoQ during a baseline study visit as well as for 4 weeks at home.

    Treatment: MitoQ

  • PlaceboPlacebo, for comparison

    The investigators will compare the effects of MitoQ to a group receiving a placebo sugar pill. Participants will be randomized into receiving MitoQ or placebo. Participants will orally ingest the placebo pill during a baseline study visit as well as for 4 weeks at home.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07938203, who can take part
Record updated
16 November 2026